Sanford Guide ID Update features current developments in infectious diseases, curated by the Sanford Guide Editorial Board. Links marked with an asterisk (*) provide details to Web Edition subscribers, while all other links are universal. If you would like to automatically receive our monthly ID Updates by e-mail, subscribe now.
 

MARCH 2018

Sanford Guide to Antimicrobial Therapy 2018

• New print editions of the Sanford Guide to Antimicrobial Therapy are expected to be available within the next two weeks. To learn more about what updates are included or to pre-order books, visit our Online Store.

Drug Safety Communications

• The US FDA is advising caution when considering the use of clarithromycin* in patients with heart disease because of the potential for increased long-term risk of heart problems or death. This recommendation is based on a review of the results of a 10-year follow-up study of patients with coronary heart disease from a large clinical trial that first observed this safety issue. The full Drug Safety Communication can be found here.

New Generic Approval

• Tenofovir Disoproxil Fumarate* tablets (150 mg, 200 mg, 250 mg, 300 mg).
• See Abbreviated New Drug Approvals (ANDAs) for further information. Contact manufacturer(s) for product availability information.

Newly Released Treatment Guidelines

• Belgian guidelines for the use of non-occupational HIV post-exposure prophylaxis* (Acta Clin Belg 2018 Feb 12 [Epub ahead of print]). These guidelines update the 2009 version.
• Clinical practice guidelines for Clostridium difficile* infection in adults and children from the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) (Clin Infect Dis 2018 Feb 15 [Epub ahead of print]). These joint guidelines update the 2010 version and are available on the IDSA website.
• Guidelines for antibiotic selection in the treatment of acute invasive Pseudomonas aeruginosa* infections from the Spanish Society of Chemotherapy (Rev Esp Quimioter 2018 Feb 23 [Epub ahead of print]). These guidelines are available on the journal website.
• Guidelines for the clinical management of odontogenic infections from the Japanese Association for Infectious Diseases and the Japanese Society of Chemotherapy (J Infect Chemother 2018 Mar 1 [Epub ahead of print]). The guidelines are available on the journal website.
• Guidelines for the clinical management of patients with neurocysticercosis* from the IDSA and the American Society of Tropical Medicine and Hygiene (Clin Infect Dis 2018 Feb 22 [Epub ahead of print]). These guidelines are available on the IDSA website.
• Guidelines for the outpatient management of fever and neutropenia in adults treated for malignancy from the American Society of Clinical Oncology (ASCO) and IDSA (J Clin Oncol 2018 Feb 20 [Epub ahead of print]). These joint guidelines update previous work published in 2011 and 2013 and are available on the ASCO website.
• Guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacteria, prepared by a joint Working Party of the British Society for Antimicrobial Chemotherapy, the Healthcare Infection Society, and the British Infection Association (J Antimicrob Chemother 73(suppl 3):iii2, 2018). The guidelines are available on the journal website.
• Swedish consensus guidelines for the treatment of hepatitis C* virus infection in adults and children (Infect Dis (Lond) 2018 Mar 1 [Epub ahead of print]). These guidelines update the 2016 release and are available on the journal website.

Antibiotic Stewardship

• Fluoroquinolones* (FQ) are associated with serious toxicities, and the US FDA has recently cautioned prescribers to avoid using them if alternative and effective drugs are available. Nevertheless, a recent study suggests that about 5.1% of adult ambulatory FQ prescriptions are written for conditions such as viral URIs and bronchitis that don’t require antibiotics, and 19.9% are for conditions where FQs are not considered firstline choices (sinusitis and uncomplicated UTI). Antibiotic stewardship efforts should be directed against inappropriate FQ use (Clin Infect Dis 2018 Jan 24 [Epub ahead of print]).
• Carbapenem-resistant Enterobacteriaceae (CRE), such as carbapenem-resistant Klebsiella pneumoniae (CRKP), is associated with limited treatment options and poor outcomes. In addition, resistance to last-line drugs such as colistin is increasing. In the first report of colistin heteroresistance in K. pneumoniae in the US, two multidrug-resistant CRKP urine isolates deemed colistin susceptible by clinical diagnostics were found to harbor a minor colistin-resistant subpopulation. This subpopulation became dominant when grown in the presence of colistin but returned to baseline levels when grown in media free of colistin. To assess possible in vivo relevance, mice infected with either strain did not survive the infection, even in the presence of colistin. This suggests the possibility of patients with colistin-susceptible CRKP strains failing colistin therapy and underscores the importance of improved diagnostics (MBio 9:e02448, 2018).

Drug Shortages (US)

• Antimicrobial drugs or vaccines in reduced supply or unavailable due to increased demand, manufacturing delays, product discontinuation by a specific manufacturer, or unspecified reasons:
  • [New on the list]: Ciprofloxacin injection, Dalbavancin injection
  • [Shortage recently resolved]: Ofloxacin 0.3% ophthalmic solution
  • [Continue to be in reduced supply]:
    • Aminoglycosides: Amikacin injection, Tobramycin injection
    • Cephalosporins: Cefepime, Cefotaxime injection (unavailable), Cefoxitin, Ceftazidime, Ceftriaxone, Cefuroxime injection
    • Fluoroquinolones: Ciprofloxacin oral suspension, Moxifloxacin injection
    • Penicillins: Amoxicillin/clavulanate 1000 mg/62.5 mg ER tablets, Ampicillin/sulbactam, Oxacillin injection, Penicillin G benzathine/Penicillin G procaine 1.2 million units (Bicillin C-R), Penicillin G procaine injection (unavailable), Piperacillin/tazobactam
    • Other antibacterials: Azithromycin injection, Clindamycin injection, Doxycycline injection, Erythromycin lactobionate injection (unavailable), Metronidazole injection, Mupirocin calcium 2% cream, Mupirocin calcium 2% nasal ointment (unavailable), Vancomycin injection
    • Antifungal drugs: Fluconazole injection
    • Antiparasitic drugs: None
    • Antiviral drugs: Oseltamivir oral suspension
    • Vaccines: Hepatitis A Virus Vaccine Inactivated (Vaqta), Hepatitis B vaccine recombinant, Yellow Fever vaccine (unavailable)
• Antimicrobial drugs newly discontinued: Quinidine gluconate IV (in December 2017). Product distribution will continue until expiration of current stock (March 2019).
  • Recent discontinuations: Terbinafine granules (in May 2017), MenHibrix (in February 2017), Elvitegravir (Vitekta, in December 2016), Peginterferon alfa-2b (in February 2016; 50 mcg vials still available in limited quantities), Boceprevir (in December 2015), Permethrin 1% topical lotion (in September 2015)
• For detailed information including estimated resupply dates, see http://www.ashp.org/DrugShortages

Sanford Guide ID Update features current developments in infectious diseases, curated by the Sanford Guide Editorial Board. Links marked with an asterisk (*) provide details to Web Edition subscribers, while all other links are universal. If you would like to automatically receive our monthly ID Updates by e-mail, subscribe now.
 

FEBRUARY 2018

New Drug Approvals

• Biktarvy* (bictegravir, emtricitabine, tenofovir alafenamide) for the treatment of HIV-1 infection in adults with no prior antiretroviral treatment history, or to replace the current regimen in a patient virologically suppressed on a stable regimen for at least three months with no history of treatment failure or known substitutions associated with resistance to bictegravir, emtricitabine, or TAF. Recommended dosage: one tablet once daily, with or without food.
• Symfi Lo* (efavirenz, lamivudine, tenofovir disoproxil fumarate) for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg. Recommended dosage: one tablet once daily on an empty stomach, preferably at bedtime to improve tolerability of CNS side effects.
• Firvanq (vancomycin oral solution), indicated for the treatment of C. difficile* associated diarrhea in adults and pediatric patients <18 years of age, and also for the treatment of enterocolitis caused by Staph. aureus (including MRSA) in adults and pediatric patients <18 years of age. Product availability: kits containing vancomycin powder (3.75, 7.5, 10.5, or 15 gm) and grape-flavored diluent that provide final drug concentrations of 25 mg/mL and 50 mg/mL after reconstitution. Expected product launch: early April, 2018.

New FDA-approved Indications

• Ceftazidime-avibactam* is now indicated for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae in patients 18 years of age or older. The drug was previously approved for complicated intra-abdominal infection (in combination with metronidazole) and complicated UTI, including pyelonephritis.

From the Centers for Disease Control and Prevention

• February 9 CDC update on widespread influenza activity, including an audio recording. Click here.
• Weekly US Influenza Surveillance Report. Click here.
• The 2018 recommended immunization schedule for children and adolescents aged 18 years or younger. Click here.
• The 2018 recommended immunization schedule for adults aged 19 or older. Click here.
• Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) and CDC regarding prevention of hepatitis B infection in the US (MMWR Recomm Rep 67:1, 2018). Available for download here.

Newly Released Treatment Guidelines

• Clinical guidelines for the diagnosis and treatment of catheter-related bloodstream infection from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Society of Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) (Med Intensiva 42:5, 2018). The last Spanish catheter-related infections guidelines were published in 2004. The new guidelines are available for download on the SEIMC and SEMICYUC websites.
• 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients (Urol Int 2018 Jan 17 [Epub ahead of print]). This is an update of the 2010 version and is available for download on the Karger website.
• 2017 update of the guideline for epidemiology, diagnosis, and treatment of adult patients with nosocomial pneumonia from the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy, the German Radiological Society and the Society for Virology (Pneumologie 72:15, 2018). This is an update of the 2012 version.
• Guidelines for the diagnosis and treatment of community-acquired pneumonia in adults who present to the hospital from the Dutch Working Party on Antibiotic Policy in collaboration with the Dutch Association of Chest Physicians, the Dutch Society for Intensive Care, and the Dutch College of General Practitioners (Neth J Med 76:4, 2018). These guidelines update the 2011 version and are available for download on the journal website.

Drug Shortages (US)

• Antimicrobial drugs or vaccines in reduced supply or unavailable due to increased demand, manufacturing delays, product discontinuation by a specific manufacturer, or unspecified reasons:
  • [New on the list]: Azithromycin injection, Oseltamivir oral suspension
  • [Shortage recently resolved]: Penicillin G benzathine
  • [Continue to be in reduced supply]:
    • Aminoglycosides: Amikacin injection, Tobramycin injection
    • Cephalosporins: Cefepime, Cefotaxime injection (unavailable), Cefoxitin, Ceftazidime, Ceftriaxone, Cefuroxime injection
    • Fluoroquinolones: Ciprofloxacin oral suspension, Moxifloxacin injection, Ofloxacin 0.3% ophthalmic solution
    • Penicillins: Amoxicillin/clavulanate 1000 mg/62.5 mg ER tablets, Ampicillin/sulbactam, Oxacillin injection, Penicillin G benzathine/Penicillin G procaine 1.2 million units (Bicillin C-R), Penicillin G procaine injection (unavailable), Piperacillin/tazobactam
    • Other antibacterials: Clindamycin injection, Doxycycline injection, Erythromycin lactobionate injection (unavailable), Metronidazole injection, Mupirocin calcium 2% cream, Mupirocin calcium 2% nasal ointment (unavailable), Vancomycin injection
    • Antifungal drugs: Fluconazole injection
    • Antiparasitic drugs: None
    • Antiviral drugs: None
    • Vaccines: Hepatitis A Virus Vaccine Inactivated (Vaqta), Hepatitis B vaccine recombinant, Yellow Fever vaccine (unavailable)
• Antimicrobial drugs newly discontinued: Quinidine gluconate IV (in December 2017). Product distribution will continue until expiration of current stock (March 2019).
  • Recent discontinuations: Terbinafine granules (in May 2017), MenHibrix (in February 2017), Elvitegravir (Vitekta, in December 2016), Peginterferon alfa-2b (in February 2016; 50 mcg vials still available in limited quantities), Boceprevir (in December 2015), Permethrin 1% topical lotion (in September 2015)
• For detailed information including estimated resupply dates, see http://www.ashp.org/menu/DrugShortages

Sanford Guide ID Update features current developments in infectious diseases, curated by the Sanford Guide Editorial Board. Links marked with an asterisk (*) provide details to Web Edition subscribers, while all other links are universal. If you would like to automatically receive our monthly ID Updates by e-mail, subscribe now.
 

JANUARY 2018

New Drug Approvals

• XEPI (ozenoxacin 1% cream) is indicated for the topical treatment of impetigo due to S. aureus or S. pyogenes in patients 2 months of age and older. Ozenoxacin is a member of a new generation of non-fluorinated quinolones. Recommended dosage: apply a thin layer to the affected area twice daily x5 days. Product availability: 10-, 30-, and 45-gram tubes.

First-Time Generic Approvals (US)

• Capreomycin injection, 1 gram per vial. Mylan Laboratories Ltd., approved November 27, 2017.
• Praziquantel tablets, 600 mg. Par Pharmaceutical Inc., approved November 27, 2017.
• Note: newly approved generic drugs are not always available on or after the approval date shown. Contact the listed manufacturer for further availability information.

New FDA Website for Breakpoint Updates

• The 21^st Century Cures Act, signed into law on December 13, 2016, requires the FDA to post information online about FDA’s recognition of antimicrobial susceptibility test interpretive criteria (breakpoints) established by a standards development organization (SDO), and online lists of exceptions or additions to the recognized breakpoints established by the SDO. This online approach will allow the FDA to more quickly communicate updated breakpoints than by updating and re-updating product labeling. Click here for antibacterials and here for antifungals.

Newly Released Treatment Guidelines

• Clinical guidelines for the treatment of community-acquired skin and soft tissue infection from The Korean Society of Infectious Diseases and Korean Society for Chemotherapy, with support from the Korea Centers for Disease Control and Prevention (Infect Chemother 49:301, 2017). Available for download on the journal website.
• Clinical guidelines for the use of antibiotics in adults with acute upper respiratory tract infection, developed as part of the 2016 Policy Research Servicing Project by the Korea Centers for Disease Control and Prevention (Infect Chemother 49:326, 2017). Available for download on the journal website.
• Clinical practice guidelines for the diagnosis, management and treatment of hepatitis B virus infection from the Turkish Association for the Study of the Liver and Viral Hepatitis Society (Turk J Gastroenterol 28(suppl 2):73, 2017). Available for download on the journal website.
• Recommendations for the screening, diagnosis and management of hepatitis C virus infection from the Turkish Association for the Study of the Liver and Viral Hepatitis Society (Turk J Gastroenterol 28(suppl 2): 90, 2017). Available for download on the journal website.
• Clinical practice guidelines for the diagnosis, management and treatment of hepatitis delta virus infection from the Turkish Association for the Study of the Liver and Viral Hepatitis Society (Turk J Gastroenterol 28(suppl 2):84, 2017). Available for download on the journal website.

Antimicrobial agent-induced kidney stones

• Drug-induced kidney stones represent 1-2% of all kidney stones. Sulfonamides were the first drugs implicated. The two main mechanisms involved in the formation of drug-induced stones are (1) crystallization of a poorly soluble compound (± metabolites) that has high urinary excretion and is often used in high doses, and (2) induction of stone formation by a drug through its metabolic action, such as changing urinary pH or interfering with the excretion of calcium, phosphate, oxalate, or other substances. Antimicrobial agent-induced kidney stones are generally caused by the first mechanism. Here is a list of known or reasonably likely offenders.
  • Antibacterials
    • Amoxicillin, ampicillin (mainly crystals; stones rare)
    • Ceftriaxone (crystals or stones; mainly in kids)
    • Ciprofloxacin (mainly crystals; stones rare)
    • Sulfadiazine (stones or crystals)
    • Sulfamethoxazole (mainly crystals)
  • Antivirals
    • Acyclovir (crystals, not stones)
    • Atazanavir (if ritonavir-boosted)
    • Foscarnet (crystals, not stones)
    • Indinavir
    • Possible or unlikely offenders (mainly a single case report implicates the drug): darunavir, efavirenz, lopinavir, nelfinavir, raltegravir, saquinavir, tenofovir
  • Reference: Drugs 2017 Dec 20 [Epub ahead of print]).

Drug Shortages (US)

• Antimicrobial drugs or vaccines in reduced supply or unavailable due to increased demand, manufacturing delays, product discontinuation by a specific manufacturer, or unspecified reasons:
  • [New on the list]: None
    
  • [Shortage recently resolved]: Penicillin G benzathine
    
  • [Continue to be in reduced supply]:
    • Aminoglycosides: Amikacin injection, Tobramycin injection
    • Cephalosporins: Cefepime, Cefotaxime injection (unavailable), Cefoxitin, Ceftazidime, Ceftriaxone, Cefuroxime injection
    • Fluoroquinolones: Ciprofloxacin oral suspension, Moxifloxacin injection, Ofloxacin 0.3% ophthalmic solution
    • Penicillins: Amoxicillin/clavulanate 1000 mg/62.5 mg ER tablets, Ampicillin/sulbactam, Oxacillin injection, Penicillin G benzathine 900,000 units/Penicillin G procaine 300,000 units (Bicillin C-R 900/300), Penicillin G benzathine/Penicillin G procaine 1.2 million units (Bicillin C-R), Penicillin G procaine injection (unavailable), Piperacillin/tazobactam
    • Other antibacterials: Clindamycin injection, Doxycycline injection, Erythromycin lactobionate injection (unavailable), Metronidazole injection, Mupirocin calcium 2% cream, Mupirocin calcium 2% nasal ointment (unavailable), Vancomycin injection
    • Antifungal drugs: Fluconazole injection
    • Antiparasitic drugs: None
    • Vaccines: Hepatitis A Virus Vaccine Inactivated (Vaqta), Hepatitis B vaccine recombinant, Yellow Fever vaccine (unavailable)
• Antimicrobial drugs newly discontinued: None
  • Recent discontinuations: Terbinafine granules (in May 2017), MenHibrix (in February 2017), Elvitegravir (Vitekta, in December 2016), Peginterferon alfa-2b (in February 2016; 50 mcg vials still available in limited quantities), Boceprevir (in December 2015), Permethrin 1% topical lotion (in September 2015)
• For detailed information including estimated resupply dates, see http://www.ashp.org/menu/DrugShortages

Sanford Guide ID Update features current developments in infectious diseases, curated by the Sanford Guide Editorial Board. Links marked with an asterisk (*) provide details to Web Edition subscribers, while all other links are universal. If you would like to automatically receive our monthly ID Updates by e-mail, subscribe now.
 

DECEMBER 2017

New Drug Approvals

• Juluca*, an INSTI/NNRTI combination formulation of dolutegravir + rilpivirine, is a complete two-drug regimen for treatment of HIV-1 infection in adult patients who 1) are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months, 2) have no baseline pre-therapy resistance mutations, and 3) have no history of virologic treatment failure. Standard HIV-1 treatment consists of three or more drugs.

 

• Shingrix (zoster vaccine recombinant, adjuvanted) is a new vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older. The recommended administration schedule is two 0.5 mL IM doses, given first at month zero and then anytime between 2-6 months later. In late October the Advisory Committee on Immunizations Practices (ACIP) voted that this new vaccine is 1) recommended for healthy adults of age ≥50 to prevent shingles and related complications, 2) recommended for adults who previously received the current vaccine (Zostavax), and 3) the preferred vaccine for preventing shingles and related complications. These recommendations will be published in MMWR and become official policy once they are approved by the CDC director.

First-Time Generic Approvals (US)

• Darunavir ethanolate tablets, 600 mg (Teva), approved November 28.

 

• Caspofungin injection, 50 mg and 70 mg vials (Mylan, Gland Pharma), approved September 29.

Newly Released Treatment Guidelines

• New guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated hemorrhagic cystitis in hematopoietic stem cell transplant recipients from the ECIL-6 (6^th European Conference on Infections in Leukemia) have been published (J Antimicrob Chemother 2017 Sept 8 [Epub ahead of print]).

 

• Updated guidelines for the diagnosis and management of gastrointestinal complications in adult cancer patients from the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) have been published (Ann Hematol 2017 Nov 24 [Epub ahead of print]). These guidelines update the 2013 release and are available for download on the journal website.

 

• New European guidelines for the management of pelvic inflammatory disease have been published (Int J STD AIDS 2017 Jan 1 [Epub ahead of print]). The guidelines are available for download on the International Union against Sexually Transmitted Infections (IUSTI) website.

 

• Updated guidelines for primary prophylaxis of invasive fungal infections in patients with hematological malignancies from the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) have been published (Ann Hematol 2017 Dec 7 [Epub ahead of print]). These guidelines update the 2014 release and are available for download on the journal website.

Drug Shortages (US)

• Antimicrobial drugs or vaccines in reduced supply or unavailable due to increased demand, manufacturing delays, product discontinuation by a specific manufacturer, or unspecified reasons:
  • [New on the list]: None
    
  • [Shortage recently resolved]: Cefpodoxime oral suspension, Gentamicin injection
  • [Continue to be in reduced supply]:
    • Aminoglycosides: Amikacin injection, Tobramycin injection
    • Cephalosporins: Cefepime, Cefotaxime injection (unavailable), Cefoxitin, Ceftazidime, Ceftriaxone, Cefuroxime injection
    • Fluoroquinolones: Ciprofloxacin oral suspension, Moxifloxacin injection, Ofloxacin 0.3% ophthalmic solution
    • Penicillins: Amoxicillin/clavulanate 1000 mg/62.5 mg ER tablets, Ampicillin/sulbactam, Oxacillin injection, Penicillin G benzathine, Penicillin G benzathine 900,000 units/Penicillin G procaine 300,000 units (Bicillin C-R 900/300), Penicillin G benzathine/Penicillin G procaine 1.2 million units (Bicillin C-R), Penicillin G procaine injection (unavailable), Piperacillin/tazobactam
    • Other antibacterials: Clindamycin injection, Doxycycline injection, Erythromycin lactobionate injection (unavailable), Metronidazole injection, Mupirocin calcium 2% cream, Mupirocin calcium 2% nasal ointment (unavailable), Vancomycin injection
    • Antifungal drugs: Fluconazole injection
    • Antiparasitic drugs: None
    • Vaccines: Hepatitis A Virus Vaccine Inactivated (Vaqta), Hepatitis B vaccine recombinant, Yellow Fever vaccine (unavailable)
• Antimicrobial drugs newly discontinued: None
  • Recent discontinuations: Terbinafine granules (in May 2017), MenHibrix (in February 2017), Elvitegravir (Vitekta, in December 2016), Peginterferon alfa-2b (in February 2016; 50 mcg vials still available in limited quantities), Boceprevir (in December 2015), Permethrin 1% topical lotion (in September 2015)
• For detailed information including estimated resupply dates, see http://www.ashp.org/menu/DrugShortages

Sanford Guide Content Integrated into VigiLanz
 
MINNEAPOLIS, MN and SPERRYVILLE, VA. – (November 29, 2017) – VigiLanz, a digital healthcare intelligence firm, announced today that users of its market-leading clinical intelligence platform now have direct access to The Sanford Guide, the industry’s top digital infectious disease content. Integrating content from The Sanford Guide lets clinicians and pharmacists take the critical next step in the antimicrobial de-escalation process by leveraging peer-reviewed recommendations on the latest treatments—without having to exit the VigiLanz workflow.
 
Through its exclusive partnership with Sanford Guide, VigiLanz clients can access the full suite of digital infectious disease content and associate it with specific rules. Users can then search comprehensive coverage of the latest clinician-designed treatment options for infectious diseases, syndromes, and pathogens from within the VigiLanz system, driving improved patient outcomes. “The value of this partnership to our clients extends beyond their VigiLanz users to include any clinician or pharmacist in need of the actionable treatment recommendations, tailored for use in clinical scenarios, from anywhere across the enterprise,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA.
 
Noting that the company’s antimicrobial stewardship platform recently achieved the top overall satisfaction rating in the “Antimicrobial Stewardship 2017” performance report from KLAS Research, Goldsteen added that, “The Sanford Guide’s exceptional content and clinical guidance are the perfect complement to our nationally-recognized platform, advancing care quality and patient safety through industry-leading guidance on the treatment of infectious diseases.”
 
The VigiLanz clinical intelligence platform leverages real-time monitoring of thousands of patient care data elements to help improve medication safety, antimicrobial stewardship, infection prevention, quality and care management, and patient safety. Its state-of-the-art rules engine analyzes that data and pushes alerts to clinicians at the point of care when interventions and other actions are necessary, driving significant improvements in safety, efficiency, performance, and reimbursement.
 
Trusted by clinicians in over 100 countries, The Sanford Guide is optimized to minimize time-to-answer while providing comprehensive guidance at the point of care. With continually updated information based on the latest available evidence, focused anti-infective drug information, interactive dosing tables, and extensive links to references and related resources, The Sanford Guide provides actionable guidance that is accessible, concise, and reliable. “By integrating The Sanford Guide’s trusted clinical treatment recommendations with its top-rated clinical surveillance tools, VigiLanz is helping hospital and health systems take their approach to infectious disease and antimicrobial stewardship to the next level,” said Sanford Guide CEO and Managing Editor Jeb Sanford.
 
For more information on the integrated VigiLanz-Sanford Guide solution, visit Sanford Guide in booth #740 during the ASHP Midyear Clinical Meeting and Exhibition taking place Dec. 3-7 in Orlando.
 
About Sanford Guide
Since 1969, Sanford Guide has been a leader in point-of-care recommendations for the treatment of infectious diseases. Widely used by pharmacists, physicians, physician assistants, and nurses, Sanford Guide helps to improve patient care by providing carefully curated recommendations based on the latest evidence. With over 1 million users worldwide, Sanford Guide takes pride in responsiveness to customers, the development of innovative solutions, and providing content that is unparalleled in quality and clinical applicability.
 
About VigiLanz
Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.
 
Download the press release.